surpass-cvot tirzepatide trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I Original Article: Cardiovascular Outcomes with
Description
To avoid this, hold the pen firmly in place for up to 5 seconds until see the 0 icon in the dosage window
Very nicely done John and Janinne !
Further, the reduction in apoC-III levels with tirzepatide was more pronounced in patients with high baseline triglycerides, which are considered a high-risk factor for heart disease [12]
Apply for Your Assessment How Body Balance Medical Supports GLP-1 Patients Dietary information is useful
Its easy to stay motivated when you arent thinking about bad food/drink choices
Survodutide's glucagon/GLP-1 dual agonism offers a mechanistically distinct value proposition
